Announced on Medical Design & Manufacturing (MD&M) West show which started yesterday (February 8) in Anaheim, California, the US, Clariant, a global specialty chemical company, has established a global Medical and Pharmaceutical segment within its Masterbatches Business Unit to further strengthen its support for customers in these highly demanding markets.

Headed by Stephen Duckworth, the new group will manage the development, production, marketing and technical support for Clariant's MEVOPUR color masterbatches and custom performance compounds, which are manufactured exclusively for medical and pharmaceutical applications. The MEVOPUR brand is produced under specially controlled conditions at three dedicated global ISO13485 certified sites located in Lewiston, Maine in the US, Malmö in Sweden and in Singapore.

Clariant said the formation of this sector-specific organization demonstrates its commitment to provide application knowledge and product expertise tailored to the specific requirements and challenges of the medical device and pharmaceutical packaging industries. In particular, it will support customers in meeting the increasingly strict controls governing end-product ingredients and manufacturers' need to minimize risk at every stage of design, production and product approval.

According to the manufacturer, the MEVOPUR-branded color masterbatches, pre-colored compounds, standard color ranges and performance-enhancing solutions are produced under controlled, consistent and compliant conditions to help customers achieve appearance and performance enhancement for their medical device or packaging application while ensuring regulatory acceptability. MEVOPUR uses raw materials that have been biologically evaluated against USP parts 87 and 88 (Class VI devices) and/or the international standard ISO10993. Segregated manufacturing lines help reduce the risk of cross contamination, and segregated storage and change-control processes ensure consistency.

Announced on Medical Design & Manufacturing (MD&M) West show which started yesterday (February 8) in Anaheim, California, the US, Clariant, a global specialty chemical company, has established a global Medical and Pharmaceutical segment within its Masterbatches Business Unit to further strengthen its support for customers in these highly demanding markets.

Headed by Stephen Duckworth, the new group will manage the development, production, marketing and technical support for Clariant's MEVOPUR color masterbatches and custom performance compounds, which are manufactured exclusively for medical and pharmaceutical applications. The MEVOPUR brand is produced under specially controlled conditions at three dedicated global ISO13485 certified sites located in Lewiston, Maine in the US, Malmö in Sweden and in Singapore.

Clariant said the formation of this sector-specific organization demonstrates its commitment to provide application knowledge and product expertise tailored to the specific requirements and challenges of the medical device and pharmaceutical packaging industries. In particular, it will support customers in meeting the increasingly strict controls governing end-product ingredients and manufacturers' need to minimize risk at every stage of design, production and product approval.

According to the manufacturer, the MEVOPUR-branded color masterbatches, pre-colored compounds, standard color ranges and performance-enhancing solutions are produced under controlled, consistent and compliant conditions to help customers achieve appearance and performance enhancement for their medical device or packaging application while ensuring regulatory acceptability. MEVOPUR uses raw materials that have been biologically evaluated against USP parts 87 and 88 (Class VI devices) and/or the international standard ISO10993. Segregated manufacturing lines help reduce the risk of cross contamination, and segregated storage and change-control processes ensure consistency.